JPMorgan raised the firm’s price target on Bruker (BRKR) to $55 from $50 and keeps an Overweight rating on the shares. The firm updated models in the life science tools and diagnostics group.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker Receives Buy Rating Amid Strong Financial Outlook and Margin Expansion Plans
- Bruker price target raised to $55 from $48 at Wells Fargo
- Bruker price target raised to $55 from $45 at Barclays
- Wolfe upgrades Bruker to Outperform on 2026 growth
- Bruker upgraded to Outperform from Peer Perform at Wolfe Research